Corient Private Wealth LP purchased a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 182,763 shares of the company's stock, valued at approximately $1,602,000.
A number of other hedge funds also recently modified their holdings of IBRX. Hussman Strategic Advisors Inc. bought a new stake in shares of ImmunityBio in the second quarter valued at $1,287,000. SEB Asset Management AB bought a new position in shares of ImmunityBio during the 1st quarter worth $18,770,000. Winning Points Advisors LLC bought a new position in shares of ImmunityBio during the 4th quarter worth $1,430,000. BlackRock Inc. increased its holdings in ImmunityBio by 29.4% in the 2nd quarter. BlackRock Inc. now owns 34,083,262 shares of the company's stock worth $298,399,000 after acquiring an additional 7,736,819 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in ImmunityBio by 18.5% in the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company's stock worth $64,899,000 after acquiring an additional 5,122,052 shares during the last quarter. Institutional investors own 8.58% of the company's stock.
Insider Activity
In other news, Director Cheryl Cohen sold 131,210 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total value of $1,246,495.00. Following the sale, the director directly owned 125,386 shares of the company's stock, valued at approximately $1,191,167. This represents a 51.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total transaction of $197,000.00. Following the completion of the transaction, the director owned 2,802,788 shares of the company's stock, valued at $22,085,969.44. This trade represents a 0.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 412,410 shares of company stock worth $3,753,442 over the last ninety days. Company insiders own 66.10% of the company's stock.
ImmunityBio Stock Performance
Shares of NASDAQ IBRX opened at $8.19 on Friday. ImmunityBio, Inc. has a fifty-two week low of $1.95 and a fifty-two week high of $12.43. The stock has a market cap of $8.68 billion, a PE ratio of -8.44 and a beta of 0.04. The stock has a fifty day moving average of $7.91 and a 200-day moving average of $7.88.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.14). The company had revenue of $51.24 million during the quarter, compared to analyst estimates of $49.70 million. On average, sell-side analysts predict that ImmunityBio, Inc. will post -0.44 EPS for the current year.
Analyst Ratings Changes
IBRX has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of ImmunityBio in a research report on Tuesday, June 2nd. BTIG Research reissued a "buy" rating and issued a $12.00 price target on shares of ImmunityBio in a research report on Thursday, May 21st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of ImmunityBio in a research note on Friday, July 10th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, ImmunityBio presently has a consensus rating of "Moderate Buy" and an average price target of $14.20.
Check Out Our Latest Stock Analysis on IBRX
ImmunityBio Company Profile
(
Free Report)
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Further Reading
Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
